Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1321 to 1335 of 1973 results for nice guidelines

  1. Docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer (TA26)

    This guidance has been replaced by NICE guideline CG24 [Replaced by NICE guideline CG121].

  2. Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis (HTG441)

    Evidence-based recommendations on multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis.

  3. Glitazones in the treatment of type 2 diabetes (TA63)

    This guidance has been updated and replaced by NICE guideline CG66 [partially updated by NICE guideline CG87]).

  4. The clinical effectiveness and cost effectiveness of tension-free vaginal tape for stress incontinence (TA56)

    This guidance has been updated and replaced by NICE guideline CG40. [Replaced by NICE guideline CG171 (September 2013)] 

  5. Guidance executive

    NICE's guidance executive is made up of executive directors, guidance centre directors and senior team members.

  6. Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome (TA80)

    This guidance has been replaced by recommendations 1.3.4 to 1.3.8 in NICE guideline CG94 and by recommendation 1.3.18 in NICE guideline CG172.

  7. Caesarean section (CG132)

    This guidance has been updated and replaced by NICE guideline NG192 and the recommendations on multiple pregnancy have been updated and replaced by NICE guideline NG137

  8. Sparsentan for treating primary IgA nephropathy (TA1074)

    Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults.

  9. Antimicrobial prescribing: meropenem with vaborbactam (ES21)

    Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making

  10. Temperature control to improve neurological outcomes after cardiac arrest (HTG710)

    Evidence-based recommendations on temperature control to improve neurological outcomes after cardiac arrest. This involves controlling a person’s body temperature while they are still unconscious after their heart has been restarted. Either their body is kept at a normal temperature of between 36.5°C and 37.5°C to prevent fever, or it is cooled to between 32.0°C and 36.0°C (therapeutic hypothermia).

  11. Efgartigimod for treating antibody-positive generalised myasthenia gravis (TA1069)

    Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.

  12. Zio XT for detecting cardiac arrhythmias (HTG562)

    Evidence-based recommendations on Zio XT for detecting cardiac arrhythmias.

  13. Hyperglycaemia in acute coronary syndromes: management (CG130)

    This guideline has been replaced by NICE guideline NG185.

  14. Immunisations: reducing differences in uptake in under 19s (PH21)

    This guideline has been replaced by NICE guideline NG218.